Thyrocare

Thyrocare expands Northern India presence with Polo Labs acquisition

This move will lead to Thyrocare integrating Polo Labs' 14 laboratories spread across Punjab, Haryana, and Himachal Pradesh into its existing network

Thyrocare Tech stock skyrockets 17% post Q1FY25 results; details here

Thyrocare Technologies stock surged up to 16.75 per cent at Rs 759 per share on the BSE in Wednesday's intraday trade

Thyrocare acquires Think Health Diagnostics, expands into home ECG services

With this strategic acquisition, Thyrocare will expand its footprint in the pre-policy medical check-up segment for the insurance market

Analysts cautious on mid, smallcaps; await earnings catch-up

Analysts remain cautious on mid-and-smallcap segments and suggest earnings need to catch up before the stocks start to recover

Covid-19: Analysts dump diagnostic firms for multiplexes on solid outlook

Experts believe the current news cycle may keep the stock prices of related players volatile in the near term, but any fundamental or direct impact, in the long run, remains improbable.

Thyrocare Technologies names Rahul Guha as MD & CEO

A graduate of IIM-B, Guha has spent almost 17 years at Boston Consulting Group (BCG), where he has led the healthcare and life sciences practice

Stocks to watch: Dodla Dairy, KIMS, Barbeque Nation, Thyrocare, SBI, Lupin

Realty firm Ashiana Housing on Saturday reported a consolidated net loss of Rs 5.2 crore for the quarter ending March. Its net loss stood at Rs 8.63 crore in the year-ago period

Thyrocare deal: PharmEasy founders out to build Amazon of health care

Of the three healthcare baskets that PharmEasy is targeting, it has already created a significant presence in consultation and treatment

Not insisting on board seat; only an investor: Thyrocare's A Velumani

I am an investor, and not insisting on any board seat. I am selling my entire stake of 66 per cent, says Velumani

Thyrocare investors should exit given open offer discount to current price

Investors in Thyrocare should exit given the open offer discount to the current price

PharmEasy parent to acquire 66% stake in Thyrocare for Rs 4,546 cr

PharmEasy will retain the Thyrocare brand

PharmEasy to pick up 66.1% stake in Thyrocare for Rs 4,546 crore

The combined entity will have the ability to provide diagnostics and pharmacy services to 100 million-plus Indians within 24 hours, the company said in a statement

A Velumani explains how Covid-19 testing failed us when we needed it most

The second wave has been far more explosive than anticipated, affecting over 300,000 people a day. The sheer volume of the requirement hit the industry like a tonne of bricks

Bet on these diagnostic stocks for up to 19% return as Covid-19 cases flare

According to the Union Health Ministry data, India recorded 1,03,558 coronavirus infections on Sunday, pushing the nationwide Covid tally to 1.25 crore

Coronavirus pandemic: Stocks of diagnostic firms could prove safe bets

Though details of Covid19-testing reimbursement are crucial to ascertain the earnings impact, other growth levers remain intact

Metropolis, Thyrocare say they will start tests for coronavirus from today

They would start collecting samples for testing from today. For starters, this would happen in Mumbai

Generation Next to step in at Thyrocare

Velumani is inducting both his children into business with bigger share in the hands of daughter

Thyrocare IPO subscribed 56% on Day 1

The Rs 480-crore IPO is priced between Rs 420 and Rs 446 a share.

Thyrocare raises Rs 144 cr from anchor investors

Its IPO price band is Rs 420-446 per share